Hikma Pharmaceuticals Plc (LON:HIK) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.00 and traded as high as $1,805.50. Hikma Pharmaceuticals shares last traded at $1,771.00, with a volume of 426,775 shares.
A number of research firms have weighed in on HIK. Peel Hunt restated a “hold” rating on shares of Hikma Pharmaceuticals in a research report on Monday, July 29th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a GBX 1,700 ($22.21) price target on shares of Hikma Pharmaceuticals in a report on Tuesday, June 18th. Finally, Barclays reaffirmed an “equal weight” rating and issued a GBX 1,800 ($23.52) price target on shares of Hikma Pharmaceuticals in a report on Friday, May 3rd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of GBX 1,808.57 ($23.63).
The company has a market capitalization of $4.29 billion and a P/E ratio of 15.20. The firm’s fifty day simple moving average is GBX 1,782.57. The company has a debt-to-equity ratio of 37.54, a quick ratio of 1.17 and a current ratio of 1.87.
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals.
Read More: What is a CD ladder?
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.